公开(公告)号：US20240216405A1

公开(公告)日：2024-07-04

申请号：US18514227

申请日：2023-11-20

申请人： HIBM Research Group, Inc.

发明人： Daniel Kohan DARVISH ,  Yadira VALLES-AYOUB

IPC分类号： A61K31/7012 ,  A01K67/0275 ,  A01K67/0278 ,  A61D19/04 ,  C12N9/12 ,  C12N9/90 ,  C12Q1/6883 ,  G01N33/50 ,  G01N33/573

CPC分类号： A61K31/7012 ,  A01K67/0275 ,  A01K67/0278 ,  A61D19/04 ,  C12N9/1205 ,  C12N9/90 ,  C12Q1/6883 ,  G01N33/5038 ,  G01N33/573 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  A01K2267/0318 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Y207/0106 ,  C12Y501/03002 ,  G01N2333/91215 ,  G01N2333/99 ,  G01N2500/10

摘要： Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof; and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed.

公开(公告)号：US11732282B2

公开(公告)日：2023-08-22

申请号：US16765833

申请日：2018-11-15

申请人： Chr. Hansen HMO GmbH

发明人： Markus Helfrich ,  Stefan Jennewein

IPC分类号： C12P19/02 ,  A23L33/125 ,  A23L33/00 ,  A61K31/7012 ,  C12P19/26 ,  C07H1/08 ,  C07H3/08 ,  C07H1/06 ,  C07H7/027

CPC分类号： C12P19/02 ,  A23L33/125 ,  A23L33/40 ,  A61K31/7012 ,  C07H1/06 ,  C07H1/08 ,  C07H3/08 ,  C07H7/027 ,  C12P19/26

摘要： The present invention concerns an efficient way to isolate L-fucose from a fermentation broth. The L-fucose contained in the fermentation broth is produced by microbial fermentation (bacterial or yeasts). The inventive process comprises a step of removing biomass from the fermentation broth, a step of subjecting the resulting solution to at least one of a cationic ion exchanger treatment and an anionic ion exchanger treatment and a step of removing salts after the ion exchanger treatment. The process can provide L-fucose in powder form, in granulated form as well as in form of L-fucose crystals.

公开(公告)号：US20230181735A1

公开(公告)日：2023-06-15

申请号：US18063902

申请日：2022-12-09

申请人： MEDIMMUNE, LLC

发明人： Nicole KALLEWAARD-LELAY ,  Raburn MALLORY ,  Gabriel ROBBIE ,  Song REN

IPC分类号： A61K39/42 ,  A61K31/215 ,  C07K16/10 ,  A61P31/16 ,  A61K31/13 ,  A61K31/7012

CPC分类号： A61K39/42 ,  A61K31/215 ,  C07K16/1018 ,  A61P31/16 ,  A61K31/13 ,  A61K31/7012 ,  C07K2317/76 ,  A61K2039/545

摘要： Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

公开(公告)号：US20180264122A1

公开(公告)日：2018-09-20

申请号：US15762180

申请日：2016-09-22

申请人： Vitality Biopharma, Inc

发明人： Brandon J. Zipp ,  Janee M. Hardman ,  Robert T. Brooke

IPC分类号： A61K47/54 ,  A61K31/352

CPC分类号： A61K47/549 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/352 ,  A61K31/7012 ,  A61K31/7016 ,  A61K31/7034 ,  A61P1/10 ,  A61P25/00 ,  A61P29/00 ,  C07H15/10 ,  C07H15/203

摘要： The present invention relates to cannabinoid glycoside prodrugs suitable for site- and tissue-specific delivery of cannabinoid molecules. The present invention also relates to methods of forming the cannabinoid glycoside prodrugs through glycosyltransferase mediated glycosylation of cannabinoid molecules.

公开(公告)号：US20180235988A1

公开(公告)日：2018-08-23

申请号：US15553561

申请日：2016-02-23

申请人： The United States of America, as represented by the Secretary, Department of Health and Human

发明人： Marjan Huizing ,  May C. Malicdan ,  Nuria Carrillo

IPC分类号： A61K31/7008 ,  A61P9/00 ,  A61K9/00 ,  A61K45/06 ,  A61K47/20 ,  A61K9/50 ,  A61K9/127

CPC分类号： A61K31/7008 ,  A61K9/0053 ,  A61K9/127 ,  A61K9/50 ,  A61K31/7012 ,  A61K31/702 ,  A61K31/7088 ,  A61K45/06 ,  A61K47/20 ,  A61P9/00

摘要： Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress.

公开(公告)号：US20180207145A1

公开(公告)日：2018-07-26

申请号：US15924952

申请日：2018-03-19

申请人： GlaxoSmithKline Intellectual Property (No. 2) Limited

发明人： Michael WASHBURN

IPC分类号： A61K31/4462 ,  A61K31/5513 ,  A61K9/08 ,  A61K47/40 ,  A61K9/00 ,  A61K39/42 ,  C07K16/10 ,  A61K31/4196 ,  A61K31/4184 ,  A61K31/519 ,  A61K31/7068 ,  A61K31/433 ,  A61K31/41 ,  A61K31/422 ,  A61K31/437 ,  A61K31/55 ,  A61K31/4545 ,  A61K31/5377 ,  C12N15/113 ,  A61K31/7056 ,  A61K31/215 ,  A61K31/351

CPC分类号： A61K31/4462 ,  A61K9/0019 ,  A61K9/0073 ,  A61K9/08 ,  A61K31/215 ,  A61K31/351 ,  A61K31/41 ,  A61K31/4184 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/433 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/5513 ,  A61K31/7012 ,  A61K31/7056 ,  A61K31/7068 ,  A61K39/42 ,  A61K47/40 ,  C07K16/1027 ,  C07K2317/24 ,  C12N15/1131 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

摘要： Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.

公开(公告)号：US20180050055A1

公开(公告)日：2018-02-22

申请号：US15238253

申请日：2016-08-16

申请人： HAFIZ AHMED ,  HAITHAM A. BADR ,  KEVIN J. YAREMA

发明人： HAFIZ AHMED ,  HAITHAM A. BADR ,  KEVIN J. YAREMA

IPC分类号： A61K31/7012 ,  C12N5/09

CPC分类号： A61K31/7012 ,  C12N5/0693 ,  C12N2501/999

摘要： Drug delivery to the cancer cells during its treatment is challenging. Most of the cancer drug cannot reach to the target because of its complex membrane physiology, drug resistance, and mutability. Establishment of a potential target molecule or domain on the cancer cell is the rate limiting step for the successful drug delivery. Cancer is characterized by abnormal energy metabolism shaped by nutrient deprivation that malignant cells experience during various stages of tumor development. This patent demonstrated a new method of establishing a new target domain that could have enormous importance for the drug delivery during cancer treatment. The inventors showed how nutrient-deprived cancer cells become involved in robust membrane glycan display while treating with nucleotide sugar such as sialic acid and that glycosylated membrane domain become a target domain of cancer cell treatment. The inventor showed how to use the lectin, by making a compound with nanomagnetic particles in the treatment of cancer cells. Using the nanomagnetic lectin inventor established an innovative method to treat the cancer cells and showed how prostate cancer cells in the xenograft can be regressed using the technology in the non-limited Example-1 section. In conclusion, nucleotide sugar supplement to nutrient deprived cancer cells enforce them to robust membrane glycan display which could be a novel tool for the successful drug delivery during cancer cell treatment.

公开(公告)号：US20180036358A1

公开(公告)日：2018-02-08

申请号：US15785034

申请日：2017-10-16

申请人： Life Science Nutrition AS

发明人： Jan Remmereit

IPC分类号： A61K36/03 ,  A23L33/105 ,  A23L33/00 ,  A61K31/05 ,  A61K36/87 ,  A61K31/7012 ,  A61K31/715 ,  A61K31/727 ,  A61K31/737 ,  A61K36/481 ,  A23L29/256 ,  A61K31/352

CPC分类号： A61K36/03 ,  A23L29/256 ,  A23L33/105 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/30 ,  A23V2200/31 ,  A23V2200/318 ,  A23V2200/33 ,  A23V2200/332 ,  A23V2250/2116 ,  A23V2250/51 ,  A23V2250/5438 ,  A61K31/05 ,  A61K31/352 ,  A61K31/7012 ,  A61K31/715 ,  A61K31/727 ,  A61K31/737 ,  A61K36/481 ,  A61K36/87 ,  A61K2300/00

摘要： The present invention relates to the field of nutraceuticals, and in particular to nutraceuticals comprising sulfated polysaccharides, Astragalus polysaccharides, resveratrol, and combinations thereof. These compositions find use in inducing physiological responses such, decreasing body fat, increasing lean body mass, alleviating the symptoms of colds, preventing the onset of colds, increasing energy, increasing the feeling of well-being in subjects, and improving skin tone and appearance.

公开(公告)号：US09879066B2

公开(公告)日：2018-01-30

申请号：US15215738

申请日：2016-07-21

申请人： Genentech, Inc.

发明人： Ning Chai ,  Jacqueline McBride ,  Lee Swem

IPC分类号： C07K16/10 ,  A61K45/06 ,  A61K31/196 ,  A61K31/7012 ,  A61K39/395 ,  A61K31/215 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K31/196 ,  A61K31/215 ,  A61K31/7012 ,  A61K39/39575 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  A61K2300/00

摘要： The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.

公开(公告)号：US09744140B2

公开(公告)日：2017-08-29

申请号：US15353213

申请日：2016-11-16

申请人： Enteris BioPharma, Inc.

发明人： Stephen M. Carl ,  John Stanley Vrettos ,  William Stern

IPC分类号： A61K31/65 ,  A61K31/351 ,  A61K31/7036 ,  A61K9/52 ,  A61K9/48 ,  A61K47/18 ,  A61K31/216 ,  A61K47/12 ,  A61K47/10 ,  A61K47/14 ,  A61K31/122 ,  A61K31/397 ,  A61K31/64 ,  A61K31/7012 ,  A61K9/00

CPC分类号： A61K9/4891 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/122 ,  A61K31/216 ,  A61K31/351 ,  A61K31/397 ,  A61K31/64 ,  A61K31/65 ,  A61K31/7012 ,  A61K31/7036 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/183 ,  A61K47/186

摘要： The present invention provides pharmaceutical compositions suitable for oral delivery and methods of treating subjects in need thereof. The pharmaceutical compositions of the present invention enhance bioavailability of at least one compound classified as BCS Class II, BCS Class III or BCS Class IV.